TRACE
Trace a source
tape live—manual reviewONevidenceREQUIREDjson/trace.jsontracked horizons1D · 7D · 30D · 90Ddisclaimernot financial advicetape live—manual reviewONevidenceREQUIREDjson/trace.jsontracked horizons1D · 7D · 30D · 90Ddisclaimernot financial advice
publisheddirectional thesisLONGyoutubenot an explicit trade

LLY directional thesis

Lilly just got a real oral weight-loss pill approved while copycats sell an oral version with zero human studies and a RICO lawsuit hanging over it.

$925.29entry snapshot
pendingcurrent snapshot
— pendingsince mention
“The day before this article ran, the day before, Lilly's oral got approved. It was not tirzepatide. In fact, it wasn't even a peptide.”
101:12claim_id mcl_f1f9020f53bfc282c6open evidence ↗
Classification directional thesis

Human-reviewed public claim.

Evidence span 101:12

Evidence URL, source timestamp, and excerpt are attached to this permanent claim page.

Correction path available

Creators or reviewers can request reclassification, context, or entity corrections without erasing the source record.

Machine-readable claim
{
  "version": "market-claims.v1",
  "claim": {
    "id": "mcl_f1f9020f53bfc282c6",
    "url": "/trace/claims/mcl_f1f9020f53bfc282c6",
    "status": "PUBLISHED",
    "claimType": "DIRECTIONAL_THESIS",
    "direction": "LONG",
    "claimText": "Lilly just got a real oral weight-loss pill approved while copycats sell an oral version with zero human studies and a RICO lawsuit hanging over it.",
    "confidence": 0.72,
    "expert": {
      "slug": "tbpn",
      "displayName": "TBPN",
      "kind": "PERSON",
      "status": "UNCLAIMED",
      "avatarUrl": "/api/avatars/f01e70d9-d",
      "url": "/trace/experts/tbpn",
      "claimed": false
    },
    "primaryEntity": {
      "kind": "ASSET",
      "assetClass": "EQUITY",
      "symbol": "LLY",
      "name": "LLY",
      "exchange": null,
      "confidence": 0.78
    },
    "evidence": {
      "evidenceUrl": "https://www.youtube.com/watch?v=wrnhYB2uIA8&t=6072s",
      "sourceUrl": "https://youtube.com/watch?v=wrnhYB2uIA8",
      "timecode": "101:12",
      "startMs": 6072000,
      "endMs": null,
      "excerpt": "The day before this article ran, the day before, Lilly's oral got approved. It was not tirzepatide. In fact, it wasn't even a peptide."
    },
    "performance": {
      "entryPrice": 925.29,
      "currentPrice": null,
      "returnPct": null,
      "relativePct": null,
      "method": "PASTE_AUTHOR_PRICE"
    },
    "resolutionStatus": "OPEN",
    "ambiguityNotes": null,
    "horizon": "multi-year",
    "isExplicitTrade": false,
    "notFinancialAdvice": true,
    "disclaimer": "AISO tracks public statements, not verified portfolio positions. This is not financial advice."
  },
  "expert": {
    "slug": "tbpn",
    "displayName": "TBPN",
    "kind": "PERSON",
    "status": "UNCLAIMED",
    "avatarUrl": "/api/avatars/f01e70d9-d",
    "url": "/trace/experts/tbpn",
    "claimed": false
  },
  "source": {
    "platform": "YOUTUBE",
    "title": "We're Back! $1B GLP-1 Lessons. AI Funding Debates. China's 2030 Master Plan.",
    "sourceUrl": "https://youtube.com/watch?v=wrnhYB2uIA8",
    "publishedAt": "2026-04-06T19:37:41.000Z"
  },
  "evidence": {
    "evidenceUrl": "https://www.youtube.com/watch?v=wrnhYB2uIA8&t=6072s",
    "sourceUrl": "https://youtube.com/watch?v=wrnhYB2uIA8",
    "timecode": "101:12",
    "startMs": 6072000,
    "endMs": null,
    "excerpt": "The day before this article ran, the day before, Lilly's oral got approved. It was not tirzepatide. In fact, it wasn't even a peptide.",
    "quote": "The day before this article ran, the day before, Lilly's oral got approved. It was not tirzepatide. In fact, it wasn't even a peptide.",
    "speaker": "Jonathan Slotkin"
  },
  "entities": [
    {
      "kind": "ASSET",
      "assetClass": "EQUITY",
      "symbol": "LLY",
      "name": "LLY",
      "exchange": null,
      "confidence": 0.78
    }
  ],
  "marketData": {
    "entry": {
      "price": 925.29,
      "currency": "USD",
      "observedAt": "2026-04-06T19:37:41.000Z",
      "method": "PASTE_AUTHOR_PRICE"
    },
    "current": null,
    "returnPct": null
  },
  "snapshots": [
    {
      "kind": "ENTRY",
      "symbol": "LLY",
      "assetClass": "EQUITY",
      "price": 925.29,
      "probability": null,
      "currency": "USD",
      "provider": "paste.trade",
      "providerSymbol": "xyz:LLY",
      "observedAt": "2026-04-06T19:37:41.000Z",
      "method": "PASTE_AUTHOR_PRICE",
      "returnPct": null,
      "relativePct": null
    }
  ]
}

AISO Market Calls classifies public statements from public sources. A classification such as long thesis, short thesis, or explicit call describes the content of the public statement and does not prove that the speaker actually entered, exited, or held a position. Market performance shown is calculated from public market data around the source publication or timestamp. It is not investment advice.